Adalimumab WAC 기준 처방 수량(YoY, MoM, M/S)

Humira CF(Abbvie, 오리지널): 205.6k units (-6.6%, -15.3%, 73.7%)
Humira non-CF(Abbvie,오리지널): 37.5k units (-10.9%, -11.8%, 13.4%)
Amjevita(Amgen,BS): 6.5k units (231.8%, +2.2%, 2.3%)
Hadlima(삼성에피스,BS): 14.3k units (n/a, +19.9%, 5.1%)
Yuflyma(셀트리온,BS): 0.2k units (n/a, -2.3%, 0.1%)
Clytezo(베링거인겔하임,BS): 1.3k units (n/a, +5.7%, 0.5%)
Hyrimoz(산도즈,BS): 11.9k units (n/a, -12.8%, 4.3%)
Yusimry(코헤러스,BS): 0.9k units (n/a, -10.6%, 0.3%)
Idacio(프레제니우스 카비,BS): 0.4k units (n/a, -4.6%, 0.1%)
Hulio(마일란,BS): 0.5k units (n/a, -11.0%, 0.2%)
참 기가 찹니다.
포스트무버는 삼바에피스 하드리마로
굳어지는거 아닐지...
유플 점유율 0.1%가 뭡니까?
서구라가 직접 영업중인데도 이꼬라지면
푸~~~